Hostname: page-component-8448b6f56d-dnltx Total loading time: 0 Render date: 2024-04-23T19:32:38.931Z Has data issue: false hasContentIssue false
  • English
  • Français

Pharmacological Acute Migraine Treatment Strategies: Choosing the Right Drug for a Specific Patient

Published online by Cambridge University Press:  01 July 2015

Irene Worthington ,
Tamara Pringsheim ,
Marek J. Gawel ,
Jonathan Gladstone ,
Paul Cooper ,
Esma Dilli ,
Michel Aube ,
Elizabeth Leroux ,
Werner J. Becker  and
on behalf of the Canadian Headache Society Acute Migraine Treatment Guideline Development Group
Irene Worthington
Affiliation:
Sunnybrook Health Sciences Centre, Toronto, Ontario
Tamara Pringsheim
Affiliation:
University of Calgary and the Hotchkiss Brain Institute, Calgary, Alberta
Marek J. Gawel
Affiliation:
Sunnybrook Health Sciences Centre, Toronto, Ontario Rouge Valley Health System – Centenary, Toronto, Ontario Women's College Hospital, Toronto, Ontario, Canada
Jonathan Gladstone
Affiliation:
Sunnybrook Health Sciences Centre, Toronto, Ontario Gladstone Headache Clinic, Toronto, Ontario
Paul Cooper
Affiliation:
University of Western Ontario, London, Ontario
Esma Dilli
Affiliation:
University of British Columbia, Vancouver, British Columbia
Michel Aube
Affiliation:
McGill University, Montreal, Quebec
Elizabeth Leroux
Affiliation:
University of Montreal, Montreal, Quebec
Werner J. Becker*
Affiliation:
University of Calgary and the Hotchkiss Brain Institute, Calgary, Alberta
*
Division of Neurology, 12th Floor, Foothills Hospital, 1403 29th St NW, Calgary, Alberta, T2N 2T9, Canada
Rights & Permissions [Opens in a new window]

Abstract:

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Background:

In our targeted review (Section 2), 12 acute medications received a strong recommendation for use in acute migraine therapy while four received a weak recommendation for use. Strong recommendations were made to avoid use of two other medications, except for exceptional circumstances. Two anti-emetics received strong recommendations for use as needed.

Objective:

To organize the available acute migraine medications into acute migraine treatment strategies in order to assist the practitioner in choosing a specific medication(s) for an individual patient.

Methods:

Acute migraine treatment strategies were developed based on the targeted literature review used for the development of this guideline (Section 2), and a general literature review. Expert consensus groups were used to refine and validate these strategies.

Results:

Based on evidence for drug efficacy, drug side effects, migraine severity, and coexistent medical disorders, our analysis resulted in the formulation of eight general acute migraine treatment strategies. These could be grouped into four categories: 1) two mild-moderate attack strategies, 2) two moderate-severe attack or NSAID failure strategies, 3) three refractory migraine strategies, and 4) a vasoconstrictor unresponsive-contraindicated strategy. In addition, strategies were developed for menstrual migraine, migraine during pregnancy, and migraine during lactation. The eight general treatment strategies were coordinated with a “combined acute medication approach” to therapy which used features of both the “stratified” and the “step care across attacks” approaches to acute migraine management.

Conclusions:

The available medications for acute migraine treatment can be organized into a series of strategies based on patient clinical features. These strategies may help practitioners make appropriate acute medication choices for patients with migraine.

Type
SECTION III
Information
Canadian Journal of Neurological Sciences , Volume 40 , Issue S3 , September 2013 , pp. S33 - S62
Copyright
Copyright © The Canadian Journal of Neurological 2014

References

1.Lipton, RB, Stewart, WF, Stone, AM, Lainez, MJ, Sawyer, JP, Disability in Strategies of Care Study, group. Stratified care vs step care strategies for migraine: the Disability in Strategies of Care (DISC) Study: A randomized trial.[see comment]. JAMA. 2000;284:2599–605.Google Scholar
2.Lipton, RB, Baggish, JS, Stewart, WF, Codispoti, JR, Fu, M.Efficacy and safety of acetaminophen in the treatment of migraine: results of a randomized, double-blind, placebo-controlled, population-based study. Arch Intern Med. 2000;160:3486–92.Google Scholar
3.Prior, MJ, Codispoti, JR, Fu, M.A randomized, placebo-controlled trial of acetaminophen for treatment of migraine headache. Headache. 2010;50:819–33.Google Scholar
4.Hamalainen, ML, Hoppu, K, Valkeila, E, Santavuori, P.Ibuprofen or acetaminophen for the acute treatment of migraine in children: a double-blind, randomized, placebo-controlled, crossover study. Neurology. 1997;48:103–7.Google Scholar
5.Larsen, BH, Christiansen, LV, Andersen, B, Olesen, J.Randomized double-blind comparison of tolfenamic acid and paracetamol in migraine. Acta Neurol Scand. 1990;81:464–7.Google Scholar
6.Ottani, A, Leone, S, Sandrini, M, Ferrari, A, Bertolini, A.The analgesic activity of paracetamol is prevented by the blockade of cannabinoid CB1 receptors. Eur J Pharmacol. 2006;531:280–1.Google Scholar
7.Cooke, LJ, Becker, WJ.Migraine prevalence, treatment and impact: the canadian women and migraine study. Can J neurol Sci. 2010; 37:580–7.CrossRefGoogle ScholarPubMed
8.Suthisisang, C, Poolsup, N, Kittikulsuth, W, Pudchakan, P, Wiwatpanich, P.Efficacy of low-dose ibuprofen in acute migraine treatment: systematic review and meta-analysis. Ann Pharmacother. 2007;41:1782–91.CrossRefGoogle ScholarPubMed
9.Rabbie, R, Derry, S, Moore, RA, McQuay, HJ.Ibuprofen with or without an antiemetic for acute migraine headaches in adults. Cochrane Database Syst Rev. 2010;008039.CrossRefGoogle Scholar
10.Diener, HC, Bussone, G, de Liano, H, et al.Placebo-controlled comparison of effervescent acetylsalicylic acid, sumatriptan and ibuprofen in the treatment of migraine attacks. Cephalalgia. 2004;24:947–54.Google Scholar
11.Suthisisang, C, Poolsup, N, Suksomboon, N, Lertpipopmetha, V, Tepwitukgid, B.Meta-analysis of the efficacy and safety of naproxen sodium in the acute treatment of migraine. Headache. 2010;50:808–18.CrossRefGoogle ScholarPubMed
12.Derry, S, Rabbie, R, Moore, RA.Diclofenac with or without an antiemetic for acute migraine headaches in adults. Cochrane Database Syst Rev. 2012;2:008783.Google Scholar
13.Diener, HC, Montagna, P, Gacs, G, et al.Efficacy and tolerability of diclofenac potassium sachets in migraine: a randomized, double-blind, cross-over study in comparison with diclofenac potassium tablets and placebo. Cephalalgia. 2006;26:537–47.Google Scholar
14.Kirthi, V, Derry, S, Moore, RA, McQuay HJ. Aspirin with or without an antiemetic for acute migraine headaches in adults. Cochrane Database Syst Rev. 2010;4:008041.Google Scholar
15.Lampl, C, Voelker, M, Diener, HC.Efficacy and safety of 1,000 mg effervescent aspirin: individual patient data meta-analysis of three trials in migraine headache and migraine accompanying symptoms. J Neurol. 2007;254:705–12.Google Scholar
16.Shields, KG, Goadsby, PJ.Serotonin receptors modulate trigeminovascular responses in ventroposteromedial nucleus of thalamus: a migraine target? Neurobiol Dis. 2006;23:491–501.Google Scholar
17.Loder, E.Triptan therapy in migraine. N Engl J Med. 2010;363: 63–70.Google Scholar
18.Goldstein, DJ, Roon, KI, Offen, WW, et al.Selective seratonin 1F (5-HT(1F)) receptor agonist LY334370 for acute migraine: a randomised controlled trial. Lancet. 2001;358:1230–4.Google Scholar
19.Ferrari, MD, Goadsby, PJ, Roon, KI, Lipton, RB.Triptans (serotonin, 5-HT1B/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials.[see comment][erratum appears in Cephalalgia. 2003 Feb;23(1):71.]. Cephalalgia. 2002;22:633–58.Google Scholar
20.Cady, RK, Freitag, FG, Mathew, NT, et al.Allodynia-associated symptoms, pain intensity and time to treatment: predicting treatment response in acute migraine intervention. Headache. 2009;49:350–63.CrossRefGoogle ScholarPubMed
21.Bigal, ME, Serrano, D, Buse, D, Scher, A, Stewart, WF, Lipton, RB.Acute migraine medications and evolution from episodic to chronic migraine: a longitudinal population-based study. Headache. 2008;48:1157–68.Google Scholar
22.Anonymous Treatment of migraine attacks with sumatriptan. The Subcutaneous Sumatriptan International Study Group. N Engl J Med. 1991;325:316–21.Google Scholar
23.Gawel, MJ, Worthington, I, Maggisano, A.A systematic review of the use of triptans in acute migraine.[see comment]. [Review] [74 refs]. Can J Neurol Sci. 2001;28:30–41.CrossRefGoogle Scholar
24.Tfelt-Hansen, P, De Vries, P, Saxena, PRTriptans in migraine: a comparative review of pharmacology, pharmacokinetics and efficacy. Drugs. 2000;60:1259–87.Google Scholar
25.Gladstone, JP, Gawel, M.Newer formulations of the triptans: advances in migraine management. [Review] [116 refs]. Drugs. 2003;63:2285–305.Google Scholar
26.Rapoport, AM, Tepper, SJ, Bigal, ME, Sheftell, FD.The triptan formulations : how to match patients and products. [Review] [75 refs]. CNS Drugs. 2003;17:431–47.CrossRefGoogle Scholar
27.Dodick, DW, Lipton, RB, Ferrari, MD, et al.Prioritizing treatment attributes and their impact on selecting an oral triptan: results from the TRIPSTAR Project. [Review] [41 refs]. Curr Pain Headache Rep. 2004;8:435–42.CrossRefGoogle Scholar
28.Ferrari, MD.Current perspectives on effective migraine treatments: are small clinical differences important for patients? [Review] [9 refs]. Med Actual. 2003;39:37–41.Google Scholar
29.Gawel, M, Aschoff, J, May, A, Charlesworth, BR, REALIZE Study T. Zolmitriptan 5 mg nasal spray: efficacy and onset of action in the acute treatment of migraine-results from phase 1 of the REALIZE Study. Headache. 2005;45:7–16.Google Scholar
30.Tfelt-Hansen, P.Sumatriptan for the treatment of migraine attacks-a review of controlled clinical trials. Cephalalgia. 1993;13: 238–44.Google Scholar
31.Dodick, D, Brandes, J, Elkind, A, Mathew, N, Rodichok, L.Speed of onset, efficacy and tolerability of zolmitriptan nasal spray in the acute treatment of migraine: a randomised, double-blind, placebo-controlled study. CNS Drugs. 2005;19:125–36.Google Scholar
32.Dodick, DW, Sandrini, G, Williams, P.Use of the sustained pain-free plus no adverse events endpoint in clinical trials of triptans in acute migraine. CNS Drugs. 2007;21:73–82.Google Scholar
33.Dodick, D, Lipton, RB, Martin, V, et al.Consensus statement: cardiovascular safety profile of triptans (5-HT agonists) in the acute treatment of migraine. [Review] [66 refs]. Headache. 2004; 44:414–25.CrossRefGoogle Scholar
34.Modgill, G, Jette, N, Wang, JL, Becker, WJ, Patten, SB.A population-based longitudinal community study of major depression and migraine. Headache. 2012;52:422–32.Google Scholar
35.Jelinski, SE, Magnusson, JE, Becker, WJ, CHORd Study G. Factors associated with depression in patients referred to headache specialists. Neurology. 2007;68:489–95.Google Scholar
36.Wenzel, RG, Tepper, S, Korab, WE, Freitag, F.Serotonin syndrome risks when combining SSRI/SNRI drugs and triptans: is the FDA’s alert warranted? Ann Pharmacother. 2008;42:1692–6.Google Scholar
37.Evans, RW, Tepper, SJ, Shapiro, RE, Sun-edelstein, C, Tietjen, GE.The FdA alert on serotonin syndrome with use of triptans combined with selective serotonin reuptake inhibitors or selective serotonin-norepinephrine reuptake inhibitors: American Headache Society position paper. Headache. 2010;50: 1089–99.Google Scholar
38.Soldin, OP, Tonning, JM; Obstetric-Fetal Pharmacology Research Unit Network. Serotonin syndrome associated with triptan monotherapy. N Engl J Med. 2008 May 15;358(20):2185–6.Google Scholar
39.Headache Classification Subcommittee of the International Headache, Society. The International Classification of Headache Disorders: 2nd edition. Cephalalgia. 2004;24:9–160.Google Scholar
40.Yates, R, Sorensen, J, Bergstrom, M, et al.Distribution of intranasal C-zolmitriptan assessed by positron emission tomography. Cephalalgia. 2005;25:1103–9.Google Scholar
41.Charlesworth, BR, Dowson, AJ, Purdy, A, Becker, WJ, Boes-Hansen, S, Farkkila, M.Speed of onset and efficacy of zolmitriptan nasal spray in the acute treatment of migraine: a randomised, double-blind, placebo-controlled, dose-ranging study versus zolmitriptan tablet. CNS Drugs. 2003;17:653–67.CrossRefGoogle Scholar
42.Ahrens, SP, Farmer, MV, Williams, DL, et al.Efficacy and safety of rizatriptan wafer for the acute treatment of migraine. Rizatriptan Wafer Protocol 049 Study Group. Cephalalgia. 1999;19:525–30.Google Scholar
43.Aurora, S, Kori, S, Barrodale, P, Nelsen, A, McDonald, S.Gastric stasis occurs in spontaneous, visually induced, and interictal migraine. Headache. 2007;47:1443–6.CrossRefGoogle ScholarPubMed
44.Aurora, SK, Kori, SH, Barrodale, P, McDonald, SA, Haseley, D.Gastric stasis in migraine: more than just a paroxysmal abnormality during a migraine attack. Headache. 2006;46:57–63.Google Scholar
45.Johannes, CB, Varas-Lorenzo, C, McQuay, LJ, Midkiff, KD, Fife, D.Risk of serious ventricular arrhythmia and sudden cardiac death in a cohort of users of domperidone: a nested case-control study. Pharmacoepidemiol drug Saf. 2010;19:881–8.Google Scholar
46.Van Noord, C, Dieleman, JP, van Herpen, G, Verhamme, K, Sturkenboom, MC.Domperidone and ventricular arrhythmia or sudden cardiac death: a population-based case-control study in the Netherlands. Drug Safety. 2010;33:1003–14.Google Scholar
47.Tokola, RA.The effect of metoclopramide and prochlorperazine on the absorption of effervescent paracetamol in migraine. Cephalalgia. 1988;8:139–47.CrossRefGoogle ScholarPubMed
48.Tokola, RA, Neuvonen, PJ.Effects of migraine attack and metoclopramide on the absorption of tolfenamic acid. Br J Clin Pharmacol. 1984;17:67–75.Google Scholar
49.Volans, GN.The effect of metoclopramide on the absorption of effervescent aspirin in migraine. Br J Clin Pharmacol. 1975;2: 57–63.Google Scholar
50.MacGregor, EA, Wilkinson, M, Bancroft, K.Domperidone plus paracetamol in the treatment of migraine. Cephalalgia. 1993;13: 124–7.Google Scholar
51.Schulman, EA, Dermott, KF.Sumatriptan plus metoclopramide in triptan-nonresponsive migraineurs. [see comment]. Headache. 2003;43:729–33.CrossRefGoogle ScholarPubMed
52.Ferrari, MD, James, MH, Bates, D, et al.Oral sumatriptan: effect of a second dose, and incidence and treatment of headache recurrences. Cephalalgia. 1994;14:330–8.Google Scholar
53.Brandes, JL, Kudrow, D, Stark, SR, et al.Sumatriptan-naproxen for acute treatment of migraine: a randomized trial. JAMA. 2007; 297:1443–54.Google Scholar
54.Geraud, G, Keywood, C, Senard, JM.Migraine headache recurrence: relationship to clinical, pharmacological, and pharmacokinetic properties of triptans. Headache. 2003;43:376–88.Google Scholar
55.Winner, P, Ricalde, O, Le Force, B, Saper, J, Margul, B.A double-blind study of subcutaneous dihydroergotamine vs subcutaneous sumatriptan in the treatment of acute migraine. [see comment]. Arch Neurol. 1996;53:180–4.Google Scholar
56.Teall, J, Tuchman, M, Cutler, N, et al.Rizatriptan (MAXALT) for the acute treatment of migraine and migraine recurrence. A placebo-controlled, outpatient study. Rizatriptan 022 Study Group. Headache. 1998;38:281–7.Google Scholar
57.Tepper, SJ, Donnan, GA, Dowson, AJ, et al.A long-term study to maximise migraine relief with zolmitriptan. Curr Med Res Opin. 1999;15:254–71.Google Scholar
58.Sheftell, F, Ryan, R, Pitman, V, Eletriptan Steering, C.Efficacy, safety, and tolerability of oral eletriptan for treatment of acute migraine: a multicenter, double-blind, placebo-controlled study conducted in the United States. Headache. 2003;43:202–13.Google Scholar
59.Rapoport, AM, Ramadan, NM, Adelman, JU, et al.Optimizing the dose of zolmitriptan (Zomig, 311C90) for the acute treatment of migraine. A multicenter, double-blind, placebo-controlled, dose range-finding study. The 017 Clinical Trial Study Group. Neurology. 1997;49:1210–8.CrossRefGoogle Scholar
60.Bates, D, Ashford, E, Dawson, R, et al.Subcutaneous sumatriptan during the migraine aura. Sumatriptan Aura Study Group. Neurology. 1994;44:1587–92.Google Scholar
61.Olesen, J, Diener, HC, Schoenen, J, Hettiarachchi, J.No effect of eletriptan administration during the aura phase of migraine. Eur J Neurol. 2004;11:671–7.Google Scholar
62.Dowson, A.Can oral 311C90, a novel 5-HT1D agonist, prevent migraine headache when taken during an aura? Eur Neurol. 1996;36:28–31.CrossRefGoogle ScholarPubMed
63.Aurora, SK, Barrodale, PM, McDonald, SA, Jakubowski, M, Burstein, R.Revisiting the efficacy of sumatriptan therapy during the aura phase of migraine. Headache. 2009;49:1001–4.Google Scholar
64.Artto, V, nissila, M, Wessman, M, Palotie, A, Farkkila, M, Kallela, M.Treatment of hemiplegic migraine with triptans. Eur J Neurol. 2007;14:1053–6.Google Scholar
65.Klapper, J, Mathew, N, Nett, R.Triptans in the treatment of basilar migraine and migraine with prolonged aura. Headache. 2001;41: 981–4.Google Scholar
66.Brandes, JL, Kudrow, D, Stark, SR, et al.Sumatriptan-naproxen for acute treatment of migraine: a randomized trial. JAMA. 2007; 297:1443–54.Google Scholar
67.Smith, TR, Sunshine, A, Stark, SR, Littlefield, DE, Spruill, SE, Alexander, WJ.Sumatriptan and naproxen sodium for the acute treatment of migraine. Headache. 2005;45:983–91.CrossRefGoogle ScholarPubMed
68.Mathew, NT, Landy, S, Stark, S, et al.Fixed-dose sumatriptan and naproxen in poor responders to triptans with a short half-life. Headache. 2009;49:971–82Google Scholar
69.Silberstein, SD, Mannix, LK, Goldstein, J, et al.Multimechanistic (sumatriptan-naproxen) early intervention for the acute treatment of migraine. Neurology. 2008;71:114–21.Google Scholar
70.Krymchantowski, AV.Naproxen sodium decreases migraine recurrence when administered with sumatriptan. Arq Neuropsiquiatr. 2000;58:428–30.Google Scholar
71.Jakubowski, M, Levy, D, Goor-Aryeh, I, Collins, B, Bajwa, Z, Burstein, R.Terminating migraine with allodynia and ongoing central sensitization using parenteral administration of COX1/COX2 inhibitors. Headache. 2005;45:850–61.Google Scholar
72.Kelley, NE, Tepper, DE.Rescue therapy for acute migraine, part 3: opioids, NSAIDs, steroids, and post-discharge medications. Headache. 2012;52:467–82.Google Scholar
73.Turkewitz, LJ, Casaly, JS, Dawson, GA, Wirth, O, Hurst, RJ, Gillette, PL.Self-administration of parenteral ketorolac tromethamine for head pain. Headache. 1992;32:452–4.Google Scholar
74.Sandrini, G, Cerbo, R, Del Bene, E, et al.Efficacy of dosing and re-dosing of two oral fixed combinations of indomethacin, prochlorperazine and caffeine compared with oral sumatriptan in the acute treatment of multiple migraine attacks: a double-blind, double-dummy, randomised, parallel group, multicentre study. Int J Clin Pract. 2007;61:1256–69.Google Scholar
75.Di Monda, V, Nicolodi, M, Aloisio, A, et al.Efficacy of a fixed combination of indomethacin, prochlorperazine, and caffeine versus sumatriptan in acute treatment of multiple migraine attacks: a multicenter, randomized, crossover trial. Headache. 2003;43:835–44.Google Scholar
76.Kelley, NE, Tepper, DE.Rescue therapy for acute migraine, part 2: neuroleptics, antihistamines, and others. Headache. 2012;52: 292–306.Google Scholar
77.Jones, EB, Gonzalez, ER, Boggs, JG, Grillo, JA, Elswick, RK Jr., Safety and efficacy of rectal prochlorperazine for the treatment of migraine in the emergency department. Ann Emerg Med. 1994;24:237–41.Google Scholar
78.McEwen, JI, O’Connor, HM, Dinsdale, HB.Treatment of migraine with intramuscular chlorpromazine. Ann Emerg Med. 1987;16: 758–63.CrossRefGoogle ScholarPubMed
79.Rozen, TD.Migraine headache: immunosuppressant therapy. Curr Treat Options Neurol. 2002;4:395–401.CrossRefGoogle ScholarPubMed
80.Colman, I, Friedman, BW, Brown, MD, et al.Parenteral dexamethasone for acute severe migraine headache: meta-analysis of randomised controlled trials for preventing recurrence. BMJ. 2008;336:1359–61.Google Scholar
81.Taheraghdam, AA, Amiri, H, Shojaan, H, Shamsvahdati, S, Houshyar, Y.Intravenous dexamethasone versus morphine in relieving of acute migraine headache. Pak J Biol Sci. 2011;14:682–7.CrossRefGoogle ScholarPubMed
82.Bigal, M, Sheftell, F, Tepper, S, Tepper, D, Ho, TW, Rapoport, A.A randomized double-blind study comparing rizatriptan, dexamethasone, and the combination of both in the acute treatment of menstrually related migraine. Headache. 2008;48: 1286–93.Google Scholar
83.Boureau, F, Joubert, JM, Lasserre, V, Prum, B, Delecoeuillerie, G.Double-blind comparison of an acetaminophen 400 mg-codeine 25 mg combination versus aspirin 1000 mg and placebo in acute migraine attack. Cephalalgia. 1994;14:156–61.Google Scholar
84.Ho, TW, Rodgers, A, Bigal, ME.Impact of recent prior opioid use on rizatriptan efficacy. A post hoc pooled analysis. Headache. 2009; 49:395–403.Google Scholar
85.Bigal, ME, Lipton, RB.Excessive acute migraine medication use and migraine progression. Neurology. 2008;71:1821–8.Google Scholar
86.De Felice, M, Porreca, F.Opiate-induced persistent pronociceptive trigeminal neural adaptations: potential relevance to opiate-induced medication overuse headache. Cephalalgia. 2009;29: 1277–84.Google Scholar
87.Madadi, P, Koren, G.Pharmacogenetic insights into codeine analgesia: implications to pediatric codeine use. Pharmacogenomics. 2008;9:1267–84.CrossRefGoogle ScholarPubMed
88.Grond, S, Sablotzki, A.Clinical pharmacology of tramadol. Clin Pharmacokinet. 2004;43:879–923.Google Scholar
89.Tepper, SJ.Medication-overuse headache. CONTINUUM: Lifelong Learning in Neurology. 2012;18:807–22.Google Scholar
90.Fisher, MA, Glass, S.Butorphanol (Stadol): a study in problems of current drug information and control. Neurology. 1997;48: 1156–60.Google Scholar
91.Bigal, ME, Lipton, RB.Acute treatment of migraine headache. Curr Treat Options neurol. 2003;5:423–30.Google Scholar
92.Gerhardt, RT, Hermstad, E, Crawford, DM, Rayfield, J, Pfaff, J, Hunter, CJ.Postdischarge secobarbital after ED migraine treatment decreases pain and improves resolution. Am J emerg Med. 2011;29:86–90.Google Scholar
93.Silberstein, SD, McCrory, DC.Ergotamine and dihydroergotamine: history, pharmacology, and efficacy. Headache. 2003;43:144–66.Google Scholar
94.Lipton, RB.Ergotamine tartrate and dihydroergotamine mesylate: safety profiles. Headache. 1997;37:S33–41.Google Scholar
95.Tfelt-Hansen, P, Saxena, PR, dahlof, C, et al.Ergotamine in the acute treatment of migraine: a review and european consensus. [Review] [84 refs]. Brain. 2000;123:9–18.Google Scholar
96.Baron, EP, Tepper, SJ.Revisiting the role of ergots in the treatment of migraine and headache. Headache. 2010;50:1353–61.Google Scholar
97.Bigal, ME, Tepper, SJ.Ergotamine and dihydroergotamine: a review. Curr Pain Headache Rep. 2003;7:55–62.CrossRefGoogle ScholarPubMed
98.MaassenVandenBrink, A, Reekers, M, Bax, WA, Ferrari, MD, Saxena, PR.Coronary side-effect potential of current and prospective antimigraine drugs. Circulation. 1998;98:25–30.Google Scholar
99.Hoskin, KL, Kaube, H, Goadsby, PJ.Central activation of the trigeminovascular pathway in the cat is inhibited by dihydroergotamine. A c-Fos and electrophysiological study. Brain. 1996;119:249–56.Google Scholar
100.Becker, WJ, Riess, CM, Hoag, J.Effectiveness of subcutaneous dihydroergotamine by home injection for migraine. Headache. 1996;36:144–8.Google Scholar
101.Weisz, MA, El-Raheb, M, Blumenthal, HJ.Home administration of intramuscular DHE for the treatment of acute migraine headache. Headache. 1994;34:371–3.Google Scholar
102.Klapper, JA, Stanton, J.Clinical experience with patient administered subcutaneous dihydroergotamine mesylate in refractory headaches. Headache. 1992;32:21–3.Google Scholar
103.Rothrock, JF.Patient information regarding subcutaneous selfadministration of dihydroergotamine (DHE). Headache. 2007;47:740.Google Scholar
104.Raskin, NH.Repetitive intravenous dihydroergotamine as therapy for intractable migraine. Neurology. 1986;36:995–7.Google Scholar
105.Silberstein, SD, Schulman, EA, Hopkins, MM.Repetitive intravenous DHE in the treatment of refractory headache. Headache. 1990;30:334–9.CrossRefGoogle ScholarPubMed
106.Eadie, MJ.Ergot of rye-the first specific for migraine. J Clin Neurosci. 2004;11:4–7.Google Scholar
107.Schmidt, R, Fanchamps, A.Effect of caffeine on intestinal absorption of ergotamine in man. Eur J Clin Pharmacol. 1974;7:213–6.Google Scholar
108.Evers, S, Gralow, I, Bauer, B, et al.Sumatriptan and ergotamine overuse and drug-induced headache: a clinicoepidemiologic study. Clin Neuropharmacol. 1999;22:201–6.Google ScholarPubMed
109.Dahlof, C.Placebo-controlled clinical trials with ergotamine in the acute treatment of migraine. [Review] [18 refs]. Cephalalgia. 1993;13:166–71.Google Scholar
110.Diener, HC, Pfaffenrath, V, Pageler, L, Peil, H, Aicher, B.The fixed combination of acetylsalicylic acid, paracetamol and caffeine is more effective than single substances and dual combination for the treatment of headache: a multicentre, randomized, double-blind, single-dose, placebo-controlled parallel group study. Cephalalgia. 2005;25:776–87.Google Scholar
111.Diener, HC, Peil, H, Aicher, B.The efficacy and tolerability of a fixed combination of acetylsalicylic acid, paracetamol, and caffeine in patients with severe headache: a post-hoc subgroup analysis from a multicentre, randomized, double-blind, single-dose, placebo-controlled parallel group study. Cephalalgia. 2011;31:1466–76.Google Scholar
112.Laska, EM, Sunshine, A, Mueller, F, Elvers, WB, Siegel, C, Rubin, A.Caffeine as an analgesic adjuvant. JAMA. 1984;251:1711–8.Google Scholar
113.Ray, WA, Varas-Lorenzo, C, Chung, CP, et al.Cardiovascular risks of nonsteroidal antiinflammatory drugs in patients after hospitalization for serious coronary heart disease. Circulation. Circ Cardiovasc Qual Outcomes. 2009;2:155–63.Google Scholar
114.Fosbol, EL, Folke, F, Jacobsen, S, et al.Cause-specific cardiovascular risk associated with nonsteroidal antiinflammatory drugs among healthy individuals. Circulation. Circ Cardiovasc Qual Outcomes. 2010;3:395–405.Google Scholar
115.Sauro, KM, Becker, WJ.Multidisciplinary treatment for headache in the Canadian healthcare setting. Can J Neurol Sci. 2008;35:46–56.CrossRefGoogle ScholarPubMed
116.MacGregor, EA, Victor, TW, Hu, X, et al.Characteristics of menstrual vs nonmenstrual migraine: a post hoc, within-woman analysis of the usual-care phase of a nonrandomized menstrual migraine clinical trial. Headache. 2010;50:528–38.Google Scholar
117.Diamond, ML, Cady, RK, Mao, L, et al.Characteristics of migraine attacks and responses to almotriptan treatment: a comparison of menstrually related and nonmenstrually related migraines. Headache. 2008;48:248–58.Google Scholar
118.Mannix, LK, Loder, E, nett, R, et al.Rizatriptan for the acute treatment of ICHD-II proposed menstrual migraine: two prospective, randomized, placebo-controlled, double-blind studies. Cephalalgia. 2007;27:414–21.Google Scholar
119.Tuchman, M, Hee, A, Emeribe, U, Silberstein, S.Efficacy and tolerability of zolmitriptan oral tablet in the acute treatment of menstrual migraine. CNS Drugs. 2006;20:1019–26.Google Scholar
120.Pringsheim, T, Davenport, WJ, Dodick, D.Acute treatment and prevention of menstrually related migraine headache: evidence-based review. Neurology. 2008;70:1555–63.Google Scholar
121.Mannix, LK, Martin, VT, Cady, RK, et al.Combination treatment for menstrual migraine and dysmenorrhea using sumatriptannaproxen: two randomized controlled trials. Obstet Gynecol. 2009;114:106–13.Google Scholar
122.Brandes, JL, Poole, A, Kallela, M, et al.Short-term frovatriptan for the prevention of difficult-to-treat menstrual migraine attacks. Cephalalgia. 2009;29:1133–48.Google Scholar
123.Silberstein, SD, Elkind, AH, Schreiber, C, Keywood, C.A randomized trial of frovatriptan for the intermittent prevention of menstrual migraine. Neurology. 2004;63:261–9.CrossRefGoogle ScholarPubMed
124.Tuchman, MM, Hee, A, Emeribe, U, Silberstein, S.Oral zolmitriptan in the short-term prevention of menstrual migraine: a randomized, placebo-controlled study. CNS Drugs. 2008;22:877–86.Google Scholar
125.Mannix, LK, Savani, N, Landy, S, et al.Efficacy and tolerability of naratriptan for short-term prevention of menstrually related migraine: data from two randomized, double-blind, placebo-controlled studies. Headache. 2007;47:1037–49.Google Scholar
126.Sances, G, Martignoni, E, Fioroni, L, Blandini, F, Facchinetti, F, nappi, G.Naproxen sodium in menstrual migraine prophylaxis: a double-blind placebo controlled study. Headache. 1990;30:705–9.Google Scholar
127.MacGregor, EA, Frith, A, Ellis, J, Aspinall, L, Hackshaw, A.Prevention of menstrual attacks of migraine: a double-blind placebo-controlled crossover study. Neurology. 2006;67:2159–63.Google Scholar
128.Almen-Christensson, A, Hammar, M, Lindh-Astrand, L, Landtblom, AM, Brynhildsen, J.Prevention of menstrual migraine with perimenstrual transdermal 17-beta-estradiol: a randomized, placebo-controlled, double-blind crossover study. Fertil Steril. 2011;96:498–500.e1.Google Scholar
129.Facchinetti, F, Sances, G, Borella, P, Genazzani, AR, Nappi, G.Magnesium prophylaxis of menstrual migraine: effects on intracellular magnesium. Headache. 1991;31:298–301.Google Scholar
130.Al-Waili, NS.Treatment of menstrual migraine with prostaglandin synthesis inhibitor mefenamic acid: double-blind study with placebo. Eur J Med Res. 2000;5:176–82.Google Scholar
131.Teichmann, A, Apter, D, Emerich, J, et al.Continuous, daily levonorgestrel/ethinyl estradiol vs. 21-day, cyclic levonorgestrel/ethinyl estradiol: efficacy, safety and bleeding in a randomized, open-label trial. Contraception. 2009;80:504–11.Google Scholar
132.Reid, RL, Fortier, MP, Smith, L, Mirkin, S, Grubb, GS, Constantine, GD.Safety and bleeding profile of continuous levonorgestrel 90 mcg/ethinyl estradiol 20 mcg based on 2 years of clinical trial data in Canada. Contraception. 2010;82:497–502.Google Scholar
133.Coffee, AL, Sulak, PJ, Kuehl, TJ.Long-term assessment of symptomatology and satisfaction of an extended oral contraceptive regimen. Contraception. 2007;75:444–9.Google Scholar
134.Sulak, P, Willis, S, Kuehl, T, Coffee, A, Clark, J.Headaches and oral contraceptives: impact of eliminating the standard 7-day placebo interval. Headache. 2007;47:27–37.Google Scholar
135.Loder, E, Rizzoli, P, Golub, J.Hormonal management of migraine associated with menses and the menopause: a clinical review. Headache. 2007;47:329–40.Google Scholar
136.Calhoun, A.Combined hormonal contraceptives: is it time to reassess their role in migraine? Headache. 2012;52:648–60.Google Scholar
137.MacGregor, EA.Contraception and headache. Headache. 2013;53:247–76.Google Scholar
138.Macintyre, PE, Schug, SA, Scott, DA, Visser, EJ, Walker, SM, APM: SE Working Group of the Australian and New Zealand College of Anaesthetists and Faculty of Pain Medicine. Acute pain management: scientific evidence. Melbourne: ANZA and FPM, 2010.Google Scholar
139.Nezvalova-Henriksen, K, Spigset, O, Nordeng, H.Effects of codeine on pregnancy outcome: Results from a large population-based cohort study. Eur J Clin Pharmacol. 2011;67:1253–61.CrossRefGoogle ScholarPubMed
140.Nezvalova-Henriksen, K, Spigset, O, Nordeng, H.Triptan exposure during pregnancy and the risk of major congenital malformations and adverse pregnancy outcomes: results from the norwegian Mother and Child Cohort Study. Headache. 2010;50:563–75.Google Scholar
141.Duong, S, Bozzo, P, Nordeng, H, Einarson, A.Safety of triptans for migraine headaches during pregnancy and breastfeeding. Can Fam Physician. 2010;56:537–9.Google ScholarPubMed
142.American Academy of Pediatrics Committee on Drugs. Transfer of drugs and other chemicals into human milk. Pediatrics. 2001;108:776–89.Google Scholar
143.Hendrickson, RG, McKeown, NJ.Is maternal opioid use hazardous to breast-fed infants? Clin Toxicol (Phila). 2012;50:1–14.Google Scholar
144.Rossi, P, Ambrosini, A, Buzzi, MG.Prodromes and predictors of migraine attack. Funct Neurol. 2005;20:185–91.Google Scholar
145.Kelman, L.The premonitory symptoms (prodrome): a tertiary care study of 893 migraineurs. Headache. 2004;44:865–72.Google Scholar
146.Schoonman, GG, Evers, DJ, Terwindt, GM, van Dijk, JG, Ferrari, MD.The prevalence of premonitory symptoms in migraine: a questionnaire study in 461 patients. Cephalalgia. 2006;26:1209–13.Google Scholar
147.Quintela, E, Castillo, J, Munoz, P, Pascual, J.Premonitory and resolution symptoms in migraine: a prospective study in 100 unselected patients. Cephalalgia. 2006;26:1051–60.Google Scholar
148.Giffin, NJ, Ruggiero, L, Lipton, RB, et al.Premonitory symptoms in migraine: an electronic diary study. Neurology 2003;60:935–40.Google Scholar
149.Waelkens, J.Dopamine blockade with domperidone: bridge between prophylactic and abortive treatment of migraine? A dose-finding study. Cephalalgia. 1984;4:85–90.Google Scholar
150.Luciani, R, Carter, D, Mannix, L, Hemphill, M, Diamond, M, Cady, R.Prevention of migraine during prodrome with naratriptan. Cephalalgia. 2000;20:122–6.Google Scholar
151.Waelkens, J.Domperidone in the prevention of complete classical migraine. Br Med J (Clin Res ed). 1982;284:944.Google Scholar
152.Becker, WJ.The premonitory phase of migraine and migraine management. Cephalalgia. 2012 Feb 15;[epub ahead of print].Google Scholar
153.Jelinski, SE, Becker, WJ, Christie, SN, et al.Clinical features and pharmacological treatment of migraine patients referred to headache specialists in Canada. Cephalalgia. 2006;26:578–88.Google Scholar
154.Derry, S, Moore, RA, McQuay, HJ.Paracetamol (acetaminophen) with or without an antiemetic for acute migraine headaches in adults. Cochrane Database Syst Rev. 2010;008040.Google Scholar
155.Lipton, RB, Grosberg, B, Singer, RP, et al.Efficacy and tolerability of a new powdered formulation of diclofenac potassium for oral solution for the acute treatment of migraine: results from the International Migraine Pain Assessment Clinical Trial (IMPACT). Cephalalgia. 2010;30:1336–45.Google Scholar
156.Buchan, P, Keywood, C, Wade, A, Ward, C.Clinical pharmacokinetics of frovatriptan. Headache. 2002;42:S54–62.Google Scholar
157.Johnston, MM, Rapoport, AM.Triptans for the management of migraine. Drugs. 2010;70:1505–18.Google Scholar
158.Derry, CJ, Derry, S, Moore, RA.Sumatriptan (subcutaneous route of administration) for acute migraine attacks in adults. Cochrane database Syst Rev. 2012;2:009665.Google Scholar
159.Derry, CJ, Derry, S, Moore, RA.Sumatriptan (intranasal route of administration) for acute migraine attacks in adults. Cochrane Database Syst Rev. 2012;2:009663.Google Scholar
160.Pascual, J, Falk, RM, Piessens, F, et al.Consistent efficacy and tolerability of almotriptan in the acute treatment of multiple migraine attacks: results of a large, randomized, double-blind, placebo-controlled study. Cephalalgia. 2000;20:588–96.Google Scholar
161.Rapoport, A, Ryan, R, Goldstein, J, Keywood, C.Dose range-finding studies with frovatriptan in the acute treatment of migraine. Headache. 2002;42:S74–83.Google Scholar
162.Derry, CJ, Derry, S, Moore, RA.Sumatriptan (oral route of administration) for acute migraine attacks in adults. Cochrane Database Syst Rev. 2012;2:008615.Google Scholar
163.Pryse-Phillips, WE, Dodick, DW, Edmeads, JG, et al.Guidelines for the diagnosis and management of migraine in clinical practice. Canadian Headache Society. [see comment][erratum appears in CMAJ 1997 Nov 15;157(10):1354]. [Review] [160 refs]. CMAJ. 1997;156:1273–87.Google Scholar